RE: Singer Capital Markets Review21 Oct 2022 10:31
Poolbeg continues to rapidly expand its portfolio of assets which currently includes POLB 001, a small molecule immunomodulator for severe Influenza which entered the clinic in July 2022 with intial results expected by the end of 2022 at which point Poolbeg plans to rapidly out-licence or parter for potentially significant upfronts plus milestones and royalties. POLB 002, a first-in-class, intranasally administered, RNA-based immunotherapy for respiratory virus infections and POLB 003, an intramuscular Melioidosis vaccine. The Company is also developing an Oral Vaccine Delivery Platform and as well as progressing its Artificial Intelligence powered drug discovery program to identify pathways and drug candidates for RSV and influenza using its disease progression data.